Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4057-4066

  Teixeira, Ana L ^a,b   Ferreira, Marta ^a   Silva, Joana ^a   Gomes, Mónica ^a,b,c   Dias, Francisca ^a,b   Santos, Juliana I ^a,b   Maurício, Joaquina ^a   Lobo, Francisco ^a   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Research Department   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

miR 221 222; Noninvasive biomarkers; Plasma circulating miRs; Renal cell carcinoma

Indexed keywords

MICRORNA 221; MICRORNA 222; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; AGED; BLOOD; CANCER STAGING; GENETICS; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84902960997     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1531-3     Document Type: Article

References (57)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma. Cancer. 2009;115(S10):2273-81.
3. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s-9.
4. Sahi C, Knox JJ, Clemons M, Joshua AM, Broom R. Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol. 2010;2(2):75-83.
5. Baker CH, Pino MS, Fidler IJ. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia. 2006;8(6):470-6. (Pubitemid 44035331)
6. Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol. 2009;27(20):3274-6.
7. Heng DY, Kollmannsberger C. State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol. 2009;16 Suppl 1:S16-23.
8. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006;107(1):37-45. (Pubitemid 43939028)
9. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779-90. (Pubitemid 351860207)
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
11. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2013;25:25.
12. Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 2009;96(7):702-10.
13. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer - new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21(3):470-9.
14. Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics. 2010;11(5):629-32.
15. Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006;38(Suppl):S20-4.
16. Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, et al. A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population. PLoS One. 2012;7(10):e46566.
17. Calore F, Lovat F, Garofalo M. Non-coding RNAs and cancer. Int J Mol Sci. 2013;14(8):17085-110.
18. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87. (Pubitemid 26072233)
19. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell. 2009;136(4):777-93.
20. Teixeira AL, Gomes M, Medeiros R. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front Genet. 2012;3(286):7.
21. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol. 2012;7(9):1528-33.
22. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897-912.
23. Xu L, Liang YN, Luo XQ, Liu XD, Guo HX. Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2011;32(3):178-81.
24. Catto JWF, Alcaraz A, Bjartell AS, de Vere WR, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder and kidney cancer: a systematic review. Eur Urol. 2011;59:671-81.
25. Shah MY, Calin GA. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011;3(8):56.
26. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.
27. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15(16):5073-81.
28. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.
29. Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, Marrelli D, et al. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch. 2008;453(5):449-55.
30. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10(55):1479-5876.
31. Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012;36(4):391-4.
32. Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J, et al. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway. Pharmacogenomics. 2013;14(14):1793-803.
33. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44(1):53-8.
34. Zhao A, Li G, Peoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115-20.
35. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17(1):F1-17. doi:ERC-09-0172.
36. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.
37. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 2011;59(5):721-30.
38. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011;6(9):e25787.
39. Zhou L, Yang H. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One. 2011;6(9):e23936.
40. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(4):1387-92. (Pubitemid 32165508)
41. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A. 2007;104(32):13092-7. (Pubitemid 351737598)
42. Shah M, Calin G. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Medicine. 2011;3(8):56.
43. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25(10):1674-80.
44. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem. 2012;287(17):13952-8.
45. Sun Y, Yu S, Liu Y, Wang F, Xiao H. Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients. Int J Endocrinol. 2013;128735(10):11.
46. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013;4(5):350-7.
47. Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, et al. miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med. 2011;40(7):560-6.
48. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004;23(3):786-94. (Pubitemid 38241279)
49. Ge H, Cao YY, Chen LQ, Wang YM, Chen ZF, Wen DG, et al. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis Esophagus. 2008;21(5):409-15.
50. Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther. 2007;14(6):543-9. (Pubitemid 46788333)
51. Liu Y, Cui H, Wang W, Li L, Wang Z, Yang S, et al. Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. Int J Biochem Cell Biol. 2013;45(11):2643-50.
52. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30(9):1082-97.
53. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897-903.
54. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27 (Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699-708. (Pubitemid 47236875)
55. Abben KK, Luth TH, Janssen-Heijnen ML. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer. 2008;44:1701-9.
56. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827-36.
57. Furniss D, Harnden P, Ali N, Royston P, Eisen T, Oliver RT, et al. Prognostic factors for renal cell carcinoma. Cancer Treat Rev. 2008;34:407-26.